NEW YORK--(BUSINESS WIRE)--The Law Offices of Vincent Wong is investigating the Board of Directors of ZymoGenetics, Inc. (NasdaqGM: ZGEN) for possible breaches of fiduciary duty and other violations of state law in connection with their attempt to sell the Company to Bristol-Myers Squibb Co. ("Bristol-Myers Squibb") (NYSE: BMY). Under the terms of the proposed transaction, ZymoGenetics shareholders will receive $9.75 in cash for each share of ZymoGenetics common stock they own for a total transaction value of approximately $885 million.
The investigation concerns whether the ZymoGenetics Board of Directors breached their fiduciary duties to ZymoGenetics stockholders by failing to adequately shop the Company before entering into this transaction and whether Bristol-Meyers Squibb is underpaying for ZymoGenetics shares.
If you own common stock in ZymoGenetics and wish to obtain additional information, contact Vincent Wong, Esq. either via email firstname.lastname@example.org, by telephone at 212.584.2740, or visit http://www.wongesq.com/zymogenetics-zgen.html.
Vincent Wong, Esq. is an experienced attorney that has represented investors in securities litigations involving financial fraud and violations of shareholder rights.